Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is required to regenerate tetrahydrofolate, a form of folate essential for synthesising purine nucleotides and thymidylate. By inhibiting this pathway, the drug reduces DNA, RNA and protein production, leading to decreased proliferation of rapidly dividing cells such as activated lymphocytes and cancer cells, thereby exerting immunosuppressive and cytotoxic effects.

The dose of Metoject Pen is individualized by the prescribing healthcare professional based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Physicians calculate the appropriate amount and frequency, and patients should follow the exact regimen provided on the prescription label without making any changes on their own.

Methotrexate is generally contraindicated during pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential should use effective contraception while receiving the drug and for a period after discontinuation as advised by their clinician. Limited data exist for breastfeeding, and the medication is usually avoided; a healthcare provider should assess risks versus benefits.

To request Metoject Pen, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a quotation, confirming availability, arranging appropriate shipping (including cold‑chain if required), and handling all necessary import documentation.

Metoject Pen delivers methotrexate via a pre‑filled subcutaneous pen, offering convenient self‑administration and more consistent absorption compared with oral tablets, which can have variable bioavailability. Compared with other injectable forms, the pen design reduces preparation steps and needle handling. Alternative disease‑modifying agents, such as biologic therapies, target specific cytokines, whereas methotrexate provides a broad immunosuppressive effect at a lower cost.

Metoject Pen should be stored at 2‑8 °C (refrigerated). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking the device. If the product must be transported, maintain the cold‑chain using insulated containers and temperature‑monitoring packs to preserve stability.

Metoject Pen is a pre‑filled, single‑use pen designed for subcutaneous injection. After confirming the prescribed dose, the user removes the protective cap, selects the injection site (typically the abdomen or thigh), and presses the activation button to deliver the medication. The pen automatically administers the set volume, and the needle is then safely disposed of in an approved sharps container.

Serious adverse events include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis or interstitial pneumonitis, acute kidney injury, and life‑threatening infections. Patients should be educated to report persistent abdominal pain, unexplained bruising or bleeding, shortness of breath, yellowing of the skin or eyes, and any signs of severe infection promptly to their healthcare provider.

Metoject Pen is contraindicated in individuals with known hypersensitivity to methotrexate or any excipients, those with severe hepatic impairment, uncontrolled infections, and pregnant women. Caution is also advised for patients with significant renal dysfunction, existing bone‑marrow suppression, or active pulmonary disease. A qualified clinician must evaluate each patient’s medical history before initiating therapy.